Insulet (PODD) Income from Continuing Operations (2010 - 2026)
Insulet (PODD) posted Income from Continuing Operations of 91100000.0 for Q1 2026, down 10.42% on a QoQ basis from 101700000.0 in Q4 2025, and up 156.62% year-over-year from 35500000.0 in Q1 2025.
Insulet (PODD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Insulet's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 91100000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 156.62% year-over-year to 91100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 302900000.0 (down 24.71% YoY) and the FY2025 annual result came in at 247100000.0, down 40.93% from the prior year.
- Income from Continuing Operations was 91100000.0 for Q1 2026 at Insulet, down from 101700000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 188600000.0 in Q2 2024 and bottomed at 35000000.0 in Q2 2022.
- A 5-year average of 56923529.41 and a median of 51500000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 141.27% — and 2023, when it surged 1098.08%.
- Insulet's Income from Continuing Operations stood at 17000000.0 in 2022, then soared by 508.24% to 103400000.0 in 2023, then fell by 2.61% to 100700000.0 in 2024, then advanced by 0.99% to 101700000.0 in 2025, then dropped by 10.42% to 91100000.0 in 2026.
- Business Quant data shows PODD's Income from Continuing Operations at 91100000.0 in Q1 2026, 101700000.0 in Q4 2025, and 87600000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Insulet | 11.08 Bn | 10.60 Bn | 529.10 Mn | 91.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.10 Mn |
| Dec 31, 2025 | 101.70 Mn |
| Sep 30, 2025 | 87.60 Mn |
| Jun 30, 2025 | 22.50 Mn |
| Mar 31, 2025 | 35.50 Mn |
| Dec 31, 2024 | 100.70 Mn |
| Sep 30, 2024 | 77.50 Mn |
| Jun 30, 2024 | 188.60 Mn |
| Mar 31, 2024 | 51.50 Mn |
| Dec 31, 2023 | 103.40 Mn |
| Sep 30, 2023 | 51.90 Mn |
| Jun 30, 2023 | 27.30 Mn |
| Mar 31, 2023 | 23.80 Mn |
| Dec 31, 2022 | 17.00 Mn |
| Sep 30, 2022 | -5.20 Mn |
| Jun 30, 2022 | -35.00 Mn |
| Mar 31, 2022 | 27.80 Mn |
| Dec 31, 2021 | 29.20 Mn |
| Sep 30, 2021 | 12.60 Mn |
| Jun 30, 2021 | -25.00 Mn |